Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Growth in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 31,099 shares, an increase of 360.2% from the May 14th total of 6,757 shares. Based on an average daily volume of 125,406 shares, the short-interest ratio is presently 0.2 days. Currently, 3.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ BJDX traded up $0.15 during mid-day trading on Friday, hitting $4.89. The stock had a trading volume of 62,830 shares, compared to its average volume of 847,857. Bluejay Diagnostics has a 1 year low of $1.62 and a 1 year high of $16.68. The business has a 50 day moving average price of $2.36 and a two-hundred day moving average price of $2.76. The firm has a market cap of $5.06 million, a P/E ratio of -0.42 and a beta of 0.82.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.